Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk shares fall 5.5% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks.
Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts
The latest trading day saw Novo Nordisk (NVO) settling at $87.17, representing a -0.99% change from its previous close.
Final Trade: GOOGL, NVO, GDX, MP
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket
Three of the major pharma companies that I follow have shown a bit of a mixed move in the premarket hours, as the markets try to get a grip on the latest demand for GLP-1 and other medicines.
Novo Nordisk Lowers Wegovy Costs for Cash-Pay Patients, Stock Up 4%
NVO offers Wegovy at a discounted price of $499 per month, which is less than half of its listed price.
Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It
Novo Nordisk's (NVO 3.84%) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance that easily beat the recovering S&P 500's (^GSPC 1.12%) 1.1% gain.
Novo Nordisk Drops Price of Weight-Loss Drug Wegovy for Some Patients Paying Out of Pocket
Novo Nordisk (NVO) is lowering the price of its popular weight-loss drug Wegovy for some patients paying out of pocket.
Novo Nordisk cuts Wegovy prices in half for cash-paying consumers
Novo Nordisk is cutting the price of its weight-loss drug, Wegovy, and selling it through a direct-to-patient online pharmacy to reach more people who aren't covered.
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
Novo Nordisk Boosts Wegovy Access With Lower Pricing and Home Delivery
On Wednesday, Novo Nordisk A/S NVO introduced NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for cash-paying patients.
Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
Novo Nordisk will offer its weight loss drug Wegovy for less than half of its usual price per month through a new direct-to-consumer online pharmacy. The cash-pay offering is available to millions of patients without insurance coverage for the blockbuster injection, such as those with Medicare.
